130 related articles for article (PubMed ID: 18604721)
21. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
22. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y; Tsurumi H; Goto N; Shimizu M; Kasahara S; Yamada T; Kanemura N; Hara T; Sawada M; Saio M; Yamada T; Takahashi T; Tomita E; Takami T; Moriwaki H
Eur J Haematol; 2006 Jun; 76(6):465-72. PubMed ID: 16494623
[TBL] [Abstract][Full Text] [Related]
23. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
24. [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].
Yin HF; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Apr; 39(2):158-62. PubMed ID: 17440591
[TBL] [Abstract][Full Text] [Related]
25. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
[TBL] [Abstract][Full Text] [Related]
27. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study.
Connor J; Ashton-Key M
Histopathology; 2007 Nov; 51(5):697-703. PubMed ID: 17927592
[TBL] [Abstract][Full Text] [Related]
28. [Gene expression profiling of diffuse large B-cell lymphoma in China].
Liu YH; Li L; Liu G; Zhuang HG; Luo DL; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):79-83. PubMed ID: 17493379
[TBL] [Abstract][Full Text] [Related]
29. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland.
Reber R; Banz Y; Garamvölgyi E; Perren A; Novak U
Swiss Med Wkly; 2013; 143():w13748. PubMed ID: 23740154
[TBL] [Abstract][Full Text] [Related]
30. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
[TBL] [Abstract][Full Text] [Related]
32. [Primary gastrointestinal diffuse large B-cell lymphoma: an immunohistochemical and prognostic study of 90 cases].
Lin L; Min M; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):220-6. PubMed ID: 21615994
[TBL] [Abstract][Full Text] [Related]
33. Identification of prognostic factors in patients with diffuse large B-cell lymphoma.
Peng F; Guo L; Yao WK; Zheng Y; Liu Y; Duan XM; Wang YP
Indian J Pathol Microbiol; 2017; 60(1):87-91. PubMed ID: 28195099
[TBL] [Abstract][Full Text] [Related]
34. [Primary central nervous system diffuse large B cell lymphoma: a clinicopathologic and molecular study].
Ma ZP; Ainiwaer B; Liu ZY; Shi XL; Cui WL; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2016 Nov; 45(11):762-768. PubMed ID: 27821230
[No Abstract] [Full Text] [Related]
35. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
[TBL] [Abstract][Full Text] [Related]
36. Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful.
Martin-Arruti M; Vaquero M; Díaz de Otazu R; Zabalza I; Ballesteros J; Roncador G; García-Orad A
Histopathology; 2012 Apr; 60(5):785-92. PubMed ID: 22321048
[TBL] [Abstract][Full Text] [Related]
37. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
[TBL] [Abstract][Full Text] [Related]
38. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
39. Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival.
Dwivedi A; Mehta A; Solanki P
Indian J Pathol Microbiol; 2015; 58(4):453-8. PubMed ID: 26549066
[TBL] [Abstract][Full Text] [Related]
40. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.
Lossos IS; Jones CD; Warnke R; Natkunam Y; Kaizer H; Zehnder JL; Tibshirani R; Levy R
Blood; 2001 Aug; 98(4):945-51. PubMed ID: 11493437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]